This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

An Update

Eric T. Wittbrodt, PharmD

Arch Intern Med. 1997;157(4):399-408.

Abstract
Myasthenia gravis is a disease of the neuromuscular junction in which normal transmission of the neuron-to-muscle impulse is impaired or prevented by acetylcholine receptor antibodies. Several classes of drugs have been associated with clinical worsening of existing myasthenia gravis, and a small subset of drugs, most notably the antirheumatic agent penicillamine, have been implicated in the pathogenesis of a variant of the disease. Recent case reports and other documented evidence link a number of specific agents with clinical worsening of myasthenia gravis.

Arch Intern Med. 1997;157:399-408

Author Affiliations
From the Department of Pharmacy Practice and Pharmacy Administration, Philadelphia College of Pharmacy and Science, Philadelphia, Pa.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Myasthenia gravis exacerbation or unmasking associated with telithromycin treatment
Perrot et al.
Neurology 2006;67:2256-2258.
ABSTRACT | FULL TEXT  

Reversible Atorvastatin-Associated External Ophthalmoplegia, Anti-acetylcholine Receptor Antibodies, and Ataxia
Negvesky et al.
Arch Ophthalmol 2000;118:427-428.
FULL TEXT  

Pulse methylprednisolone therapy for arthritis causing muscle weakness
Shanahan et al.
Ann Rheum Dis 1999;58:521-522.
FULL TEXT